Discovery of a Structurally Unique Small Molecule that Inhibits Protein Synthesis

Yale J Biol Med. 2017 Mar 29;90(1):35-43. eCollection 2017 Mar.

Abstract

Identifying and characterizing natural products and synthetic small molecules that inhibit biochemical processes such as ribosomal translation can lead to novel sources of molecular probes and therapeutics. The search for new antibiotics has been invigorated by the increasing burden of drug-resistant bacteria and has identified many clinically essential prokaryote-specific ribosome inhibitors. However, the current cohort of antibiotics is limited with regards to bacterial resistance mechanisms because of structural similarity within classes. From a high-throughput screen for translation inhibitors, we discovered a new compound, T6102, which inhibits bacterial protein synthesis in vitro, inhibits bacterial growth of Bacillus subtilis in vivo, and has a chemical structure that appears to be unique among known classes of translation-inhibiting antibiotics. T6102's unique structure compared to current clinically-utilized antibiotics makes it an exciting new candidate for the development of next-generation antibiotics.

Keywords: adamantane; drug discovery; high-throughput screening; novel antibiotic; translation inhibition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / chemistry*
  • Anti-Bacterial Agents / pharmacology*
  • Bacillus subtilis / drug effects
  • Bacillus subtilis / metabolism
  • Bacteria / drug effects
  • Bacteria / metabolism
  • Microbial Sensitivity Tests
  • Protein Biosynthesis

Substances

  • Anti-Bacterial Agents